Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With A...( - Expands the Company's Clin...)

- Expands the Company's Clinical Stage Product Portfolio -

ANN ARBOR, Mich., Feb. 6 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced that it is has completed a global licensing agreement to make, develop and commercialize products under AstraZeneca's IP and know-how regarding the use of aromatase inhibitors (AI) in combination with estrogen and progestin to treat endometriosis. This agreement expands Meditrina's clinical stage product portfolio which currently includes Femathina(TM) (MPI- 674), an AI that Meditrina is repurposing for the treatment of several serious women's health conditions, including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB). Femathina recently completed a phase II clinical trial.

"We are pleased to expand Meditrina's product portfolio with this attractive phase II product opportunity addressing a serious unmet medical need in the area of women's health," said Holly Vene, COO and Vice President, Business Development, Meditrina Pharmaceuticals, Inc. "Providing safer and more effective treatment options for the millions of women who suffer from endometriosis is an objective that fits perfectly with Meditrina's focus and commitment to improving the reproductive health and well-being of women. While Meditrina will pursue development and registration of a product for the U.S. market, it will consider partnering the product in ex-U.S. markets at the appropriate time to ensure global access to this important technology."

Endometriosis is a serious medical condition where endometrial stroma and glands that are normally present in the uterine cavity are found in other parts of the body. Endometriosis lesions can be found anywhere in the pelvic cavity: on the ovaries, the fallopian tubes, on the pelvic sidewall, the uterosacral ligaments, the cul-de-sac, the Pouch of Douglas and in the rectal- vaginal septum.

The most common symptom o
'/>"/>